Case number 1:19-cv-02368
Taiho Pharmaceutical Co., Ltd. et al v. Natco Pharma Ltd. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| May 15, 2023 | 173 | APPENDIX re (164 in 1:19-cv-02342-CFC-JLH, 130 in 1:19-cv-02309-CFC, 140 in 1:19-cv-02321-CFC, 169 in 1:19-cv-02368-CFC-JLH) Proposed Findings of Fact (Volume I of III; Exhibits DTX0008-JTX0151) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit part 1, # 2 Exhibit part 2)(Mayo, Andrew) (Entered: 05/15/2023) (Main Document) (9) |
| May 15, 2023 | 174 | APPENDIX re (144 in 1:19-cv-02321-CFC, 168 in 1:19-cv-02342-CFC-JLH, 134 in 1:19-cv-02309-CFC, 173 in 1:19-cv-02368-CFC-JLH) Appendix, (Volume II of III; Exhibits PTX0467-PTX2003) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit part 1, # 2 Exhibit part 2)(Mayo, Andrew) (Entered: 05/15/2023) (Main Document) (3) |
| May 15, 2023 | 175 | APPENDIX re (134 in 1:19-cv-02309-CFC, 173 in 1:19-cv-02368-CFC-JLH, 144 in 1:19-cv-02321-CFC, 168 in 1:19-cv-02342-CFC-JLH) Appendix, (Volume III of III; Trial Transcripts) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit Trial Transcripts)(Mayo, Andrew) (Entered: 05/15/2023) (Main Document) (3) |
| May 15, 2023 | 173 | APPENDIX re (164 in 1:19-cv-02342-CFC-JLH, 130 in 1:19-cv-02309-CFC, 140 in 1:19-cv-02321-CFC, 169 in 1:19-cv-02368-CFC-JLH) Proposed Findings of Fact (Volume I of III; Exhibits DTX0008-JTX0151) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit part 1, # 2 Exhibit part 2)(Mayo, Andrew) (Entered: 05/15/2023) (Exhibit part 1) (30) |
| May 15, 2023 | 173 | APPENDIX re (164 in 1:19-cv-02342-CFC-JLH, 130 in 1:19-cv-02309-CFC, 140 in 1:19-cv-02321-CFC, 169 in 1:19-cv-02368-CFC-JLH) Proposed Findings of Fact (Volume I of III; Exhibits DTX0008-JTX0151) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit part 1, # 2 Exhibit part 2)(Mayo, Andrew) (Entered: 05/15/2023) (Exhibit part 2) (30) |
| May 15, 2023 | 174 | APPENDIX re (144 in 1:19-cv-02321-CFC, 168 in 1:19-cv-02342-CFC-JLH, 134 in 1:19-cv-02309-CFC, 173 in 1:19-cv-02368-CFC-JLH) Appendix, (Volume II of III; Exhibits PTX0467-PTX2003) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit part 1, # 2 Exhibit part 2)(Mayo, Andrew) (Entered: 05/15/2023) (Exhibit part 1) (30) |
| May 15, 2023 | 174 | APPENDIX re (144 in 1:19-cv-02321-CFC, 168 in 1:19-cv-02342-CFC-JLH, 134 in 1:19-cv-02309-CFC, 173 in 1:19-cv-02368-CFC-JLH) Appendix, (Volume II of III; Exhibits PTX0467-PTX2003) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit part 1, # 2 Exhibit part 2)(Mayo, Andrew) (Entered: 05/15/2023) (Exhibit part 2) (30) |
| May 15, 2023 | 175 | APPENDIX re (134 in 1:19-cv-02309-CFC, 173 in 1:19-cv-02368-CFC-JLH, 144 in 1:19-cv-02321-CFC, 168 in 1:19-cv-02342-CFC-JLH) Appendix, (Volume III of III; Trial Transcripts) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit Trial Transcripts)(Mayo, Andrew) (Entered: 05/15/2023) (Exhibit Trial Transcripts) (30) |
| May 12, 2023 | 171 | Letter to The Honorable Colm F. Connolly from Andrew C. Mayo regarding Taiho's hyperlinked post-trial briefing. (Mayo, Andrew) (Entered: 05/12/2023) (1) |
| May 12, 2023 | 172 | Letter to The Honorable Colm F. Connolly from Tyler E. Cragg regarding USB Drives Containing Defendants' Hyperlinked Post-Trial Briefs - re (132 in 1:19-cv-02321-CFC, 123 in 1:19-cv-02309-CFC, 156 in 1:19-cv-02342-CFC-JLH, 161 in 1:19-cv-02368-CFC-JLH) Order,,. (Cragg, Tyler) (Entered: 05/12/2023) (2) |
| May 11, 2023 | 170 | POST TRIAL BRIEF (Defendants' Reply) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Certificate of Compliance)(Farnan, Kelly) (Entered: 05/11/2023) (Main Document) (30) |
| May 11, 2023 | 170 | POST TRIAL BRIEF (Defendants' Reply) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Certificate of Compliance)(Farnan, Kelly) (Entered: 05/11/2023) (Certificate of Compliance) (1) |
| May 4, 2023 | 168 | POST TRIAL BRIEF (Plaintiffs' Answering Post-Trial Brief) by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc.. (Balick, Steven) (Main Document 168 replaced on 5/11/2023) (nmf, ). (Entered: 05/04/2023) (30) |
| May 4, 2023 | 169 | Proposed Findings of Fact by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Balick, Steven) (Main Document 169 replaced on 5/11/2023) (nmf, ). (Entered: 05/04/2023) (30) |
| May 1, 2023 | 167 | Unopposed MOTION for Extension of Time to File Post-Trial Brief and Findings of Fact - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Biggs, Brian) (Entered: 05/01/2023) (4) |
| Apr 27, 2023 | 165 | NOTICE of Appearance by Brian A. Biggs on behalf of Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd. (Biggs, Brian) (Entered: 04/27/2023) (2) |
| Apr 27, 2023 | 166 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Raymond Miller, Shuzo Maruyama, Christian Chessman, and Megan E. Bowers - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Raymond Miller, # 4 Certification of Shuzo Maruyama, # 5 Certification of Christian Chessman, # 6 Certification of Megan E. Bowers)(Biggs, Brian) (Entered: 04/27/2023) (Main Document) (2) |
| Apr 27, 2023 | 166 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Raymond Miller, Shuzo Maruyama, Christian Chessman, and Megan E. Bowers - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Raymond Miller, # 4 Certification of Shuzo Maruyama, # 5 Certification of Christian Chessman, # 6 Certification of Megan E. Bowers)(Biggs, Brian) (Entered: 04/27/2023) (Text of Proposed Order) (1) |
| Apr 27, 2023 | 166 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Raymond Miller, Shuzo Maruyama, Christian Chessman, and Megan E. Bowers - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Raymond Miller, # 4 Certification of Shuzo Maruyama, # 5 Certification of Christian Chessman, # 6 Certification of Megan E. Bowers)(Biggs, Brian) (Entered: 04/27/2023) (Certification of Michael Sitzman) (1) |
| Apr 27, 2023 | 166 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Raymond Miller, Shuzo Maruyama, Christian Chessman, and Megan E. Bowers - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Raymond Miller, # 4 Certification of Shuzo Maruyama, # 5 Certification of Christian Chessman, # 6 Certification of Megan E. Bowers)(Biggs, Brian) (Entered: 04/27/2023) (Certification of Raymond Miller) (1) |
| Apr 27, 2023 | 166 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Raymond Miller, Shuzo Maruyama, Christian Chessman, and Megan E. Bowers - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Raymond Miller, # 4 Certification of Shuzo Maruyama, # 5 Certification of Christian Chessman, # 6 Certification of Megan E. Bowers)(Biggs, Brian) (Entered: 04/27/2023) (Certification of Shuzo Maruyama) (1) |
| Apr 27, 2023 | 166 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Raymond Miller, Shuzo Maruyama, Christian Chessman, and Megan E. Bowers - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Raymond Miller, # 4 Certification of Shuzo Maruyama, # 5 Certification of Christian Chessman, # 6 Certification of Megan E. Bowers)(Biggs, Brian) (Entered: 04/27/2023) (Certification of Christian Chessman) (1) |
| Apr 27, 2023 | 166 | MOTION for Pro Hac Vice Appearance of Attorney Michael Sitzman, Raymond Miller, Shuzo Maruyama, Christian Chessman, and Megan E. Bowers - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Michael Sitzman, # 3 Certification of Raymond Miller, # 4 Certification of Shuzo Maruyama, # 5 Certification of Christian Chessman, # 6 Certification of Megan E. Bowers)(Biggs, Brian) (Entered: 04/27/2023) (Certification of Megan E. Bowers) (1) |
| Apr 26, 2023 | 164 | MOTION for Pro Hac Vice Appearance of Attorney W. Reid Morris - filed by Natco Pharma Ltd., Natco Pharma, Inc.. (Cragg, Tyler) (Entered: 04/26/2023) (3) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Main Document) (7) |
| Apr 24, 2023 | 163 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 2 of 2 (JTX-12-part 2 through PTX-1723)) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit JTX Exhibits-part 18, # 2 Exhibit JTX Exhibits-part 19, # 3 Exhibit JTX Exhibits-part 20, # 4 Exhibit JTX Exhibits-part 21, # 5 Exhibit JTX Exhibits-part 22, # 6 Exhibit JTX Exhibits-part 23, # 7 Exhibit JTX Exhibits-part 24, # 8 Exhibit PTX Exhibits-part 1, # 9 Exhibit PTX Exhibits-part 2)(Farnan, Kelly) (Entered: 04/24/2023) (Main Document) (7) |
| Apr 24, 2023 | 163 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 2 of 2 (JTX-12-part 2 through PTX-1723)) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit JTX Exhibits-part 18, # 2 Exhibit JTX Exhibits-part 19, # 3 Exhibit JTX Exhibits-part 20, # 4 Exhibit JTX Exhibits-part 21, # 5 Exhibit JTX Exhibits-part 22, # 6 Exhibit JTX Exhibits-part 23, # 7 Exhibit JTX Exhibits-part 24, # 8 Exhibit PTX Exhibits-part 1, # 9 Exhibit PTX Exhibits-part 2)(Farnan, Kelly) (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 18) (30) |
| Apr 24, 2023 | 163 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 2 of 2 (JTX-12-part 2 through PTX-1723)) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit JTX Exhibits-part 18, # 2 Exhibit JTX Exhibits-part 19, # 3 Exhibit JTX Exhibits-part 20, # 4 Exhibit JTX Exhibits-part 21, # 5 Exhibit JTX Exhibits-part 22, # 6 Exhibit JTX Exhibits-part 23, # 7 Exhibit JTX Exhibits-part 24, # 8 Exhibit PTX Exhibits-part 1, # 9 Exhibit PTX Exhibits-part 2)(Farnan, Kelly) (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 19) (30) |
| Apr 24, 2023 | 163 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 2 of 2 (JTX-12-part 2 through PTX-1723)) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit JTX Exhibits-part 18, # 2 Exhibit JTX Exhibits-part 19, # 3 Exhibit JTX Exhibits-part 20, # 4 Exhibit JTX Exhibits-part 21, # 5 Exhibit JTX Exhibits-part 22, # 6 Exhibit JTX Exhibits-part 23, # 7 Exhibit JTX Exhibits-part 24, # 8 Exhibit PTX Exhibits-part 1, # 9 Exhibit PTX Exhibits-part 2)(Farnan, Kelly) (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 20) (30) |
| Apr 24, 2023 | 163 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 2 of 2 (JTX-12-part 2 through PTX-1723)) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit JTX Exhibits-part 18, # 2 Exhibit JTX Exhibits-part 19, # 3 Exhibit JTX Exhibits-part 20, # 4 Exhibit JTX Exhibits-part 21, # 5 Exhibit JTX Exhibits-part 22, # 6 Exhibit JTX Exhibits-part 23, # 7 Exhibit JTX Exhibits-part 24, # 8 Exhibit PTX Exhibits-part 1, # 9 Exhibit PTX Exhibits-part 2)(Farnan, Kelly) (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 21) (30) |
| Apr 24, 2023 | 163 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 2 of 2 (JTX-12-part 2 through PTX-1723)) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit JTX Exhibits-part 18, # 2 Exhibit JTX Exhibits-part 19, # 3 Exhibit JTX Exhibits-part 20, # 4 Exhibit JTX Exhibits-part 21, # 5 Exhibit JTX Exhibits-part 22, # 6 Exhibit JTX Exhibits-part 23, # 7 Exhibit JTX Exhibits-part 24, # 8 Exhibit PTX Exhibits-part 1, # 9 Exhibit PTX Exhibits-part 2)(Farnan, Kelly) (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 22) (30) |
| Apr 24, 2023 | 163 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 2 of 2 (JTX-12-part 2 through PTX-1723)) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit JTX Exhibits-part 18, # 2 Exhibit JTX Exhibits-part 19, # 3 Exhibit JTX Exhibits-part 20, # 4 Exhibit JTX Exhibits-part 21, # 5 Exhibit JTX Exhibits-part 22, # 6 Exhibit JTX Exhibits-part 23, # 7 Exhibit JTX Exhibits-part 24, # 8 Exhibit PTX Exhibits-part 1, # 9 Exhibit PTX Exhibits-part 2)(Farnan, Kelly) (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 23) (30) |
| Apr 24, 2023 | 163 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 2 of 2 (JTX-12-part 2 through PTX-1723)) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit JTX Exhibits-part 18, # 2 Exhibit JTX Exhibits-part 19, # 3 Exhibit JTX Exhibits-part 20, # 4 Exhibit JTX Exhibits-part 21, # 5 Exhibit JTX Exhibits-part 22, # 6 Exhibit JTX Exhibits-part 23, # 7 Exhibit JTX Exhibits-part 24, # 8 Exhibit PTX Exhibits-part 1, # 9 Exhibit PTX Exhibits-part 2)(Farnan, Kelly) (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 24) (23) |
| Apr 24, 2023 | 163 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 2 of 2 (JTX-12-part 2 through PTX-1723)) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit JTX Exhibits-part 18, # 2 Exhibit JTX Exhibits-part 19, # 3 Exhibit JTX Exhibits-part 20, # 4 Exhibit JTX Exhibits-part 21, # 5 Exhibit JTX Exhibits-part 22, # 6 Exhibit JTX Exhibits-part 23, # 7 Exhibit JTX Exhibits-part 24, # 8 Exhibit PTX Exhibits-part 1, # 9 Exhibit PTX Exhibits-part 2)(Farnan, Kelly) (Entered: 04/24/2023) (Exhibit PTX Exhibits-part 1) (30) |
| Apr 24, 2023 | 163 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 2 of 2 (JTX-12-part 2 through PTX-1723)) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit JTX Exhibits-part 18, # 2 Exhibit JTX Exhibits-part 19, # 3 Exhibit JTX Exhibits-part 20, # 4 Exhibit JTX Exhibits-part 21, # 5 Exhibit JTX Exhibits-part 22, # 6 Exhibit JTX Exhibits-part 23, # 7 Exhibit JTX Exhibits-part 24, # 8 Exhibit PTX Exhibits-part 1, # 9 Exhibit PTX Exhibits-part 2)(Farnan, Kelly) (Entered: 04/24/2023) (Exhibit PTX Exhibits-part 2) (30) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit DTX Exhibits-part 1) (24) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit DTX Exhibits-part 2) (8) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit DTX Exhibits-part 3) (30) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit DTX Exhibits-part 4) (30) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 1) (11) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 2) (27) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 3) (18) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 4) (28) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 5) (26) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 6) (30) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 7) (30) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 8) (30) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 9) (30) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 10) (30) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 11) (30) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 12) (30) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 13) (30) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 14) (30) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 15) (3) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 16) (30) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibit JTX Exhibits-part 17) (30) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibits DTX 0004 - 0235) (30) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibits DTX 0004 - 0235) (30) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibits DTX 0004 - 0235) (30) |
| Apr 24, 2023 | 162 | Joint APPENDIX re (130 in 1:19-cv-02321-CFC, 154 in 1:19-cv-02342-CFC-JLH, 159 in 1:19-cv-02368-CFC-JLH, 121 in 1:19-cv-02309-CFC) Proposed Findings of Fact Vol. 1 of 2 (DTX 4 through JTX-12-part 1) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Exhibit DTX Exhibits-part 1, # 2 Exhibit DTX Exhibits-part 2, # 3 Exhibit DTX Exhibits-part 3, # 4 Exhibit DTX Exhibits-part 4, # 5 Exhibit JTX Exhibits-part 1, # 6 Exhibit JTX Exhibits-part 2, # 7 Exhibit JTX Exhibits-part 3, # 8 Exhibit JTX Exhibits-part 4, # 9 Exhibit JTX Exhibits-part 5, # 10 Exhibit JTX Exhibits-part 6, # 11 Exhibit JTX Exhibits-part 7, # 12 Exhibit JTX Exhibits-part 8, # 13 Exhibit JTX Exhibits-part 9, # 14 Exhibit JTX Exhibits-part 10, # 15 Exhibit JTX Exhibits-part 11, # 16 Exhibit JTX Exhibits-part 12, # 17 Exhibit JTX Exhibits-part 13, # 18 Exhibit JTX Exhibits-part 14, # 19 Exhibit JTX Exhibits-part 15, # 20 Exhibit JTX Exhibits-part 16, # 21 Exhibit JTX Exhibits-part 17)(Farnan, Kelly) (Additional attachment(s) added on 4/25/2023: # 25 Exhibits DTX 0004 - 0235) (nmf, ). (Entered: 04/24/2023) (Exhibits DTX 0004 - 0235) (30) |
| Apr 21, 2023 | 161 | ORDER re (129 in 1:19-cv-02321-CFC, 158 in 1:19-cv-02368-CFC-JLH, 120 in 1:19-cv-02309-CFC, 153 in 1:19-cv-02342-CFC-JLH) STIPULATION and Order Regarding Post-Trial Briefing: Defendants' Opening Post-trial Brief: April 20, 2023; Defendants' Proposed Findings of Fact April 20, 2023; Plaintiffs' Answering Post-trial Brief May 4, 2023; Plaintiffs' Proposed Findings of Fact May 4, 2023; Defendants' Reply Post-trial Brief May 11, 2023; The parties will separately submit hyperlinked briefs May 12, 2023. Signed by Judge Colm F. Connolly on 4/21/2023. (nmf) (Entered: 04/21/2023) (7) |
| Apr 20, 2023 | 158 | STIPULATION and [Proposed] Order Regarding Post-Trial Briefing Schedule by Natco Pharma Ltd., Natco Pharma, Inc.. (Cragg, Tyler) (Entered: 04/20/2023) (7) |
| Apr 20, 2023 | 159 | Proposed Findings of Fact by Natco Pharma Ltd., Natco Pharma, Inc. (Attachments: # 1 Certificate of Compliance)(Farnan, Kelly) (Main Document 159 replaced on 4/28/2023) (nmf). (Attachment 1 replaced on 4/28/2023) (nmf, ). (Entered: 04/20/2023) (Main Document) (30) |
| Apr 20, 2023 | 160 | POST TRIAL BRIEF (Defendants' Opening) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Certificate of Compliance)(Farnan, Kelly) (Entered: 04/20/2023) (Main Document) (30) |
| Apr 20, 2023 | 159 | Proposed Findings of Fact by Natco Pharma Ltd., Natco Pharma, Inc. (Attachments: # 1 Certificate of Compliance)(Farnan, Kelly) (Main Document 159 replaced on 4/28/2023) (nmf). (Attachment 1 replaced on 4/28/2023) (nmf, ). (Entered: 04/20/2023) (Certificate of Compliance) (1) |
| Apr 20, 2023 | 160 | POST TRIAL BRIEF (Defendants' Opening) by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # 1 Certificate of Compliance)(Farnan, Kelly) (Entered: 04/20/2023) (Certificate of Compliance) (1) |
| Apr 11, 2023 | 156 | Official Transcript of Bench Trial held on March 29, 2023 before Chief Judge Connolly. Court Reporter/Transcriber Bonnie Archer, Email: bonnie_archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 5/2/2023. Redacted Transcript Deadline set for 5/12/2023. Release of Transcript Restriction set for 7/10/2023. (nmf) (Entered: 04/11/2023) (0) |
| Apr 11, 2023 | 157 | Official Transcript of Bench Trial held on March 30, 2023 before Chief Judge Connolly. Court Reporter/Transcriber Bonnie Archer, Email: bonnie_archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 5/2/2023. Redacted Transcript Deadline set for 5/12/2023. Release of Transcript Restriction set for 7/10/2023. (nmf) (Entered: 04/11/2023) (0) |
| Mar 28, 2023 | 155 | STIPULATION Seeking to Update Both Sides' Trial Exhibit Lists, by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Amended PTO Ex. 7, # 2 Amended PTO Ex. 8)(Balick, Steven) (Entered: 03/28/2023) (Main Document) (6) |
| Mar 28, 2023 | 155 | STIPULATION Seeking to Update Both Sides' Trial Exhibit Lists, by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Amended PTO Ex. 7, # 2 Amended PTO Ex. 8)(Balick, Steven) (Entered: 03/28/2023) (Amended PTO Ex. 7) (23) |
| Mar 28, 2023 | 155 | STIPULATION Seeking to Update Both Sides' Trial Exhibit Lists, by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Amended PTO Ex. 7, # 2 Amended PTO Ex. 8)(Balick, Steven) (Entered: 03/28/2023) (Amended PTO Ex. 8) (10) |
| Mar 27, 2023 | 151 | REDACTED VERSION of (136 in 1:19-cv-02342-CFC-JLH, 104 in 1:19-cv-02309-CFC, 140 in 1:19-cv-02368-CFC-JLH, 113 in 1:19-cv-02321-CFC) Proposed Pretrial Order (Volume I of III) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 1-25)(Mayo, Andrew) (Entered: 03/27/2023) (Main Document) (30) |
| Mar 27, 2023 | 152 | REDACTED VERSION of (141 in 1:19-cv-02368-CFC-JLH, 137 in 1:19-cv-02342-CFC-JLH, 105 in 1:19-cv-02309-CFC, 114 in 1:19-cv-02321-CFC) Proposed Pretrial Order (Volume II of III) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 26, # 2 Exhibit 27)(Mayo, Andrew) (Entered: 03/27/2023) (Main Document) (2) |
| Mar 27, 2023 | 153 | REDACTED VERSION of (138 in 1:19-cv-02342-CFC-JLH, 142 in 1:19-cv-02368-CFC-JLH, 115 in 1:19-cv-02321-CFC, 106 in 1:19-cv-02309-CFC) Proposed Pretrial Order (Volume III of III) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 28-29)(Mayo, Andrew) (Entered: 03/27/2023) (Main Document) (2) |
| Mar 27, 2023 | 154 | REDACTED VERSION of (117 in 1:19-cv-02321-CFC, 109 in 1:19-cv-02309-CFC, 141 in 1:19-cv-02342-CFC-JLH, 146 in 1:19-cv-02368-CFC-JLH) Proposed Pretrial Order, by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 1-13)(Mayo, Andrew) (Entered: 03/27/2023) (Main Document) (30) |
| Mar 27, 2023 | 153 | REDACTED VERSION of (138 in 1:19-cv-02342-CFC-JLH, 142 in 1:19-cv-02368-CFC-JLH, 115 in 1:19-cv-02321-CFC, 106 in 1:19-cv-02309-CFC) Proposed Pretrial Order (Volume III of III) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 28-29)(Mayo, Andrew) (Entered: 03/27/2023) (Exhibit 28-29) (30) |
| Mar 27, 2023 | 154 | REDACTED VERSION of (117 in 1:19-cv-02321-CFC, 109 in 1:19-cv-02309-CFC, 141 in 1:19-cv-02342-CFC-JLH, 146 in 1:19-cv-02368-CFC-JLH) Proposed Pretrial Order, by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 1-13)(Mayo, Andrew) (Entered: 03/27/2023) (Exhibit 1-13) (30) |
| Mar 27, 2023 | 152 | REDACTED VERSION of (141 in 1:19-cv-02368-CFC-JLH, 137 in 1:19-cv-02342-CFC-JLH, 105 in 1:19-cv-02309-CFC, 114 in 1:19-cv-02321-CFC) Proposed Pretrial Order (Volume II of III) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 26, # 2 Exhibit 27)(Mayo, Andrew) (Entered: 03/27/2023) (Exhibit 26) (30) |
| Mar 27, 2023 | 152 | REDACTED VERSION of (141 in 1:19-cv-02368-CFC-JLH, 137 in 1:19-cv-02342-CFC-JLH, 105 in 1:19-cv-02309-CFC, 114 in 1:19-cv-02321-CFC) Proposed Pretrial Order (Volume II of III) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 26, # 2 Exhibit 27)(Mayo, Andrew) (Entered: 03/27/2023) (Exhibit 27) (30) |
| Mar 27, 2023 | 151 | REDACTED VERSION of (136 in 1:19-cv-02342-CFC-JLH, 104 in 1:19-cv-02309-CFC, 140 in 1:19-cv-02368-CFC-JLH, 113 in 1:19-cv-02321-CFC) Proposed Pretrial Order (Volume I of III) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 1-25)(Mayo, Andrew) (Entered: 03/27/2023) (Exhibit 1-25) (30) |
| Mar 13, 2023 | 150 | NOTICE requesting Clerk to remove Hayley M. Ostrin as co-counsel. Reason for request: Left firm. (Farnan, Kelly) (Entered: 03/13/2023) (2) |
| Feb 21, 2023 | 149 | Letter to The Honorable Colm F. Connolly from Kelly E. Farnan regarding Trial Schedule. (Farnan, Kelly) (Entered: 02/21/2023) (2) |
| Feb 4, 2023 | 148 | Letter to The Honorable Colm F. Connolly from Steven J. Balick regarding Plaintiffs' Request to Postpone the February 7 Trial. (Balick, Steven) (Entered: 02/04/2023) (2) |
| Feb 3, 2023 | 147 | Letter to The Honorable Colm F. Connolly from Steven J. Balick regarding the February 7 Trial. (Balick, Steven) (Entered: 02/03/2023) (1) |
| Feb 2, 2023 | 146 | [SEALED] Proposed Pretrial Order by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Mayo, Andrew) (Entered: 02/02/2023) (0) |
| Jan 30, 2023 | 145 | Official Transcript of Pretrial Conference held on January 26, 2023 before Chief Judge Connolly. Court Reporter/Transcriber Bonnie Archer, Email: bonnie_archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 2/21/2023. Redacted Transcript Deadline set for 3/2/2023. Release of Transcript Restriction set for 5/1/2023. (nmf) (Entered: 01/30/2023) (44) |
| Jan 24, 2023 | 144 | MOTION for Pro Hac Vice Appearance of Attorney Jason M. Wiener - filed by Natco Pharma Ltd., Natco Pharma, Inc.. (Cragg, Tyler) (Entered: 01/24/2023) (3) |
| Jan 23, 2023 | 143 | SO ORDERED, re 139 STIPULATION of infringement of claim 13 of the '284 Patent by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd. Signed by Judge Colm F. Connolly on 1/23/2023. (nmf) (Entered: 01/23/2023) (5) |
| Jan 19, 2023 | 139 | STIPULATION of infringement of claim 13 of the '284 Patent by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Mayo, Andrew) (Entered: 01/19/2023) (5) |
| Jan 19, 2023 | 140 | [SEALED] Proposed Pretrial Order (Volume 1 of 3) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 1-25 (Volume 1 of 3))(Mayo, Andrew) (Entered: 01/19/2023) (0) |
| Jan 19, 2023 | 141 | [SEALED] Proposed Pretrial Order (Volume 2 of 3) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 26-27 (Volume 2 of 3))(Mayo, Andrew) (Entered: 01/19/2023) (0) |
| Jan 19, 2023 | 142 | [SEALED] Proposed Pretrial Order (Volume 3 of 3) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit 28-29 (Volume 3 of 3))(Mayo, Andrew) (Entered: 01/19/2023) (0) |
| Dec 28, 2022 | 137 | Official Transcript of In-Person Status and Scheduling Conference held on December 21, 2022 before Chief Judge Connolly. Court Reporter/Transcriber Bonnie Archer, Email: bonnie_archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/18/2023. Redacted Transcript Deadline set for 1/30/2023. Release of Transcript Restriction set for 3/28/2023. (nmf) (Entered: 12/28/2022) (83) |
| Dec 28, 2022 | 138 | STANDING ORDER REGARDING BRIEFING IN ALL CASES. Associated Cases: 1:22-cv-01611-CFC et al.(kmd) (Entered: 12/28/2022) (2) |
| Dec 27, 2022 | 136 | REDACTED VERSION of (109 in 1:19-cv-02321-CFC, 99 in 1:19-cv-02309-CFC, 21 in 1:21-cv-00838-CFC, 8 in 1:22-cv-01480-CFC, 131 in 1:19-cv-02342-CFC-JLH, 134 in 1:19-cv-02368-CFC-JLH) Letter by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Balick, Steven) (Entered: 12/27/2022) (8) |
| Dec 22, 2022 | 135 | MOTION for Pro Hac Vice Appearance of Attorney Hayley M. Ostrin - filed by Natco Pharma Ltd., Natco Pharma, Inc.. (Farnan, Kelly) (Entered: 12/22/2022) (3) |
| Dec 20, 2022 | 134 | [SEALED] Letter to The Honorable Colm F. Connolly from Steven J. Balick regarding the Parties' Joint Submission Concerning Issues Relevant to the December 21 Status and Scheduling Conference. (Balick, Steven) (Entered: 12/20/2022) (0) |
| Sep 26, 2022 | 133 | [SEALED] Joint Letter to Chief Judge Connolly from Eve H. Ormerod regarding Request for Status Conference, RE: new developments that may affect case & trial scheduling. (Ormerod, Eve) (Entered: 09/26/2022) (0) |
| Sep 22, 2022 | 132 | NOTICE requesting Clerk to remove Karen L. Beckman as co-counsel. Reason for request: Leaving Firm. (Farnan, Kelly) (Entered: 09/22/2022) (2) |
| Aug 16, 2022 | 131 | NOTICE of Appearance by Tyler E. Cragg on behalf of Natco Pharma Ltd., Natco Pharma, Inc. (Cragg, Tyler) (Entered: 08/16/2022) (2) |
| Aug 1, 2022 | 130 | Notice Requesting Removal of Co-Counsel (2) Docket Text: NOTICE requesting Clerk to remove Renee Mosley Delcollo as co-counsel. Reason for request: no longer with firm. (Delcollo, Renee) |
| Jun 30, 2022 | 126 | Redacted Document (30) Docket Text: REDACTED VERSION of (95 in 1:19-cv-02321-CFC, 118 in 1:19-cv-02342-CFC-JLH, 120 in 1:19-cv-02368-CFC-JLH, 89 in 1:19-cv-02309-CFC) Proposed Pretrial Order (Volume I of IV) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Mayo, Andrew) |
| Jun 30, 2022 | 127 | Redacted Document (30) Docket Text: REDACTED VERSION of (121 in 1:19-cv-02368-CFC-JLH, 96 in 1:19-cv-02321-CFC, 119 in 1:19-cv-02342-CFC-JLH, 90 in 1:19-cv-02309-CFC) Proposed Pretrial Order (Volume II of IV) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Mayo, Andrew) |
| Jun 30, 2022 | 128 | Redacted Document (30) Docket Text: REDACTED VERSION of (120 in 1:19-cv-02342-CFC-JLH, 97 in 1:19-cv-02321-CFC, 91 in 1:19-cv-02309-CFC, 122 in 1:19-cv-02368-CFC-JLH) Proposed Pretrial Order (Volume III of IV) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Mayo, Andrew) |
| Jun 30, 2022 | 129 | Redacted Document (30) Docket Text: REDACTED VERSION of (98 in 1:19-cv-02321-CFC, 121 in 1:19-cv-02342-CFC-JLH, 92 in 1:19-cv-02309-CFC, 123 in 1:19-cv-02368-CFC-JLH) Proposed Pretrial Order (Volume IV of IV) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Mayo, Andrew) |
| Jun 27, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: The 6/30/2022 Final Pretrial Conference and the 7/11/2022 Bench Trial are canceled. They will be rescheduled at a later date. Ordered by Judge Colm F. Connolly on 6/27/2022. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC-JLH, 1:19-cv-02368-CFC-JLH(nmf) |
| Jun 24, 2022 | 125 | Letter (1) Docket Text: Letter to The Honorable Colm F. Connolly from Steven J. Balick regarding the Parties' Joint Response to the Court's Inquiry Concerning Possible Referral to Magistrate Judge Hall. (Balick, Steven) |
| Jun 22, 2022 | N/A | Telephone Conference (0) Docket Text: Minute Entry for proceedings held before Judge Colm F. Connolly - Telephone Conference held on 6/22/2022. (Court Reporter not present.) Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC-JLH, 1:19-cv-02368-CFC-JLH(nmf) |
| Jun 21, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER Setting Teleconference: Counsel for Plaintiffs shall coordinate the call and email the dial-in information to chambers. (A Telephone Conference is set for 6/22/2022 at 10:00 AM Telephonically before Judge Colm F. Connolly.) Ordered by Judge Colm F. Connolly on 6/21/2022. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC-JLH, 1:19-cv-02368-CFC-JLH(nmf) |
| Jun 10, 2022 | 124 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendants' Joint 282 Notice filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..(Dorsney, Kenneth) |
| Jun 9, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Tiffany K. Sung for Taiho Oncology, Inc. Taiho Pharmaceutical Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC-JLH, 1:19-cv-02368-CFC-JLH(twk) |
| Apr 8, 2022 | 118 | Main Document (15) Docket Text: REPLY BRIEF re [114] MOTION to Exclude Portions of Defendants' Patent Law Expert Reports and Testimony filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # (1) Exhibit AA)(Balick, Steven) |
| Apr 8, 2022 | 118 | Exhibit AA (6) |
| Apr 8, 2022 | 119 | Main Document (5) Docket Text: REDACTED VERSION of (117 in 1:19-cv-02368-CFC-JLH) Declaration, (89 in 1:19-cv-02321-CFC) Declaration by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # (1) Exhibit 1-12)(Farnan, Kelly) |
| Apr 8, 2022 | 119 | Exhibit 1-12 (158) |
| Apr 4, 2022 | N/A | Case No Longer Referred to Mediation (0) Docket Text: CASE NO LONGER REFERRED to Chief Magistrate Judge Thynge for the purpose of exploring ADR. Pursuant to the Court's Standing Order No. 2022-2, dated March 14, 2022, "[u]nless otherwise directed by the Court, Magistrate Judges will no longer engage in alternative dispute resolution of patent and securities cases." See also 28 U.S.C. § 652(b). (Taylor, Daniel) |
| Apr 1, 2022 | 116 | Answering Brief in Opposition (26) Docket Text: ANSWERING BRIEF in Opposition re [114] MOTION to Exclude Portions of Defendants' Patent Law Expert Reports and Testimony filed by Natco Pharma Ltd., Natco Pharma, Inc..Reply Brief due date per Local Rules is 4/8/2022. (Farnan, Kelly) |
| Mar 21, 2022 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: A Certification pursuant to Local Rule 7.1.1 has been added to the MOTION to Exclude Portions of Defendants' Patent Law Expert Reports and Testimony per request of filer. Associated Cases: 1:19-cv-02321-CFC, 1:19-cv-02368-CFC-JLH(nmf) |
| Mar 21, 2022 | N/A | Motions No Longer Referred (0) Docket Text: Motions No Longer Referred: (114 in 1:19-cv-02368-CFC-JLH) MOTION to Exclude Portions of Defendants' Patent Law Expert Reports and Testimony, (103 in 1:19-cv-02342-CFC-JLH) MOTION to Exclude Certain Opinions from Dr. Allan S. Myerson Regarding Infringement of the '666 Parent by MSN's ANDA Product. The automatic referrals generated by the system have been removed for these motions. Associated Cases: 1:19-cv-02342-CFC-JLH, 1:19-cv-02368-CFC-JLH(nmf) |
| Mar 18, 2022 | 114 | Main Document (2) Docket Text: MOTION to Exclude Portions of Defendants' Patent Law Expert Reports and Testimony - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # (1) Text of Proposed Order)(Balick, Steven) (Additional attachment(s) added on 3/21/2022: # (3) Certification Pursuant to L.R. 7.1.1) (nmf) |
| Mar 18, 2022 | 114 | Text of Proposed Order (2) |
| Mar 18, 2022 | 114 | Certification Pursuant to L.R. 7.1.1 (1) |
| Mar 18, 2022 | 114 | Certification Pursuant to L.R. 7.1.1 (1) |
| Mar 18, 2022 | 115 | Main Document (27) Docket Text: OPENING BRIEF in Support re [114] MOTION to Exclude Portions of Defendants' Patent Law Expert Reports and Testimony filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..Answering Brief/Response due date per Local Rules is 4/1/2022. (Attachments: # (1) Exhibit A-E)(Balick, Steven) |
| Mar 18, 2022 | 115 | Exhibit A-E (121) |
| Feb 28, 2022 | 113 | SO ORDERED (3) Docket Text: SO ORDERED, re (112 in 1:19-cv-02368-CFC-JLH, 101 in 1:19-cv-02342-CFC-JLH, 87 in 1:19-cv-02309-CFC, 84 in 1:19-cv-02321-CFC) STIPULATION TO EXTEND TIME to File Daubert Motions to March 18, 2022, filed by Natco Pharma Ltd., Natco Pharma, Inc. Signed by Judge Colm F. Connolly on 2/28/2022. (kmd) |
| Feb 25, 2022 | 112 | Stipulation to EXTEND Time (3) Docket Text: STIPULATION TO EXTEND TIME to File Daubert Motions to March 18, 2022 - filed by Natco Pharma Ltd., Natco Pharma, Inc.. (Delcollo, Renee) |
| Feb 10, 2022 | 110 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Allan S. Myerson on February 18, 2022 filed by Natco Pharma Ltd., Natco Pharma, Inc..(Delcollo, Renee) |
| Feb 10, 2022 | 111 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Allan S. Myerson on February 14, 2022 filed by Natco Pharma Ltd., Natco Pharma, Inc..(Delcollo, Renee) |
| Feb 3, 2022 | 107 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Mohan Rao, Ph.D. on March 4, 2022, at 9:00 am filed by MSN Laboratories Private Ltd., MSN Pharmaceuticals Inc., Accord Healthcare Inc..(Ormerod, Eve) |
| Feb 3, 2022 | 108 | Notice to Take Deposition (3) Docket Text: NOTICE to Take Deposition of Richard M. Goldberg, M.D. on February 10, 2022 filed by Natco Pharma Ltd., Natco Pharma, Inc..(Delcollo, Renee) |
| Feb 3, 2022 | 109 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Stephen G. Kunin on February 24, 2022 filed by Natco Pharma Ltd., Natco Pharma, Inc..(Delcollo, Renee) |
| Jan 27, 2022 | 106 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Dr. Gregory A. Stephenson on February 4, 2022 filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Balick, Steven) |
| Jan 24, 2022 | 102 | Notice to Take Deposition (3) Docket Text: NOTICE to Take Deposition of Nicholas P. Godici on February 11, 2022 filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Jan 24, 2022 | 103 | Notice to Take Deposition (3) Docket Text: NOTICE to Take Deposition of Ivan T. Hofmann on February 23, 2022 filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Jan 24, 2022 | 104 | Notice to Take Deposition (3) Docket Text: NOTICE to Take Deposition of Dr. Mark J. Ratain on March 2, 2022 filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Jan 24, 2022 | 105 | Notice to Take Deposition (3) Docket Text: NOTICE to Take Deposition of Dr. Mark J. Ratain on January 28, 2022 filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Jan 11, 2022 | 101 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Dr. Raj Suryanarayanan on January 14, 2022 filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Jan 7, 2022 | 100 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants (1) Reply in Support of Supplemental Expert Report of Gregory A. Stephenson, Ph.D. Regarding Invalidity of U.S. Patent No. 10,457,666 and (2) Second Reply Expert Report of Nicholas P. Godici filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Dec 3, 2021 | 99 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Supplemental Responsive Expert Report of Allan S. Myerson, Ph.D. Regarding Validity of the '666 Patent filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Nov 22, 2021 | 98 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Reply Expert Report of Dr. Allan S. Myerson, Ph.D. Regarding Infringement by Natco Pharma Ltd. and Natco Pharma, Inc. and Rebuttal Expert Report of Howard S. Hochster, M.D. Regarding Infringement by the Natco Defendants filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Nov 19, 2021 | 96 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendants' (1) Reply Expert Report of Mark J. Ratain, M.D. to the Responsive Expert Report of Richard M. Goldberg, M.D. Regarding Validity Considerations of the '284 and '399 Patents and (2) Reply Expert Report of Ivan T. Hoffmann filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Nov 19, 2021 | 97 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants' (1) Reply Expert Report of Gregory A. Stephenson, Ph.D. Regarding Invalidity of U.S. Patent Nos. 9,527,833 and 10,457,666 and (2) Reply Expert Report of Nicholas P. Godici filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Oct 29, 2021 | 94 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Supplemental Opening Expert Report of Dr. Allan S. Myerson Regarding Infringement by Natco Pharma Ltd. and Natco Pharma, Inc. filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Oct 29, 2021 | 95 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants' (1) Supplemental Expert Report of Gregory A. Stephenson, Ph.D. Regarding Invalidity of U.S. Patent No. 10,457,666 and (2) Supplemental Expert Report of Nicholas P. Godici filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Oct 26, 2021 | 93 | Stipulation and Order (4) Docket Text: STIPULATION AND ORDER Concerning Authenticity and Admissibility of Certain Documents. Signed by Judge Colm F. Connolly on 10/26/2021. (kmd) |
| Oct 25, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [91] Stipulation and Proposed Order Concerning Authenticity and Admissibility of Certain Documents filed by Natco Pharma Ltd., Natco Pharma, Inc.. ORDERED by Judge Jennifer L. Hall on 10/25/2021. (cna, ) |
| Oct 22, 2021 | 90 | Redacted Document (8) Docket Text: REDACTED VERSION of [89] Notice to Take Deposition by Natco Pharma Ltd., Natco Pharma, Inc.. (Farnan, Kelly) |
| Oct 22, 2021 | 91 | Stipulation (4) Docket Text: STIPULATION and Proposed Order Concerning Authenticity and Admissibility of Certain Documents by Natco Pharma Ltd., Natco Pharma, Inc.. (Farnan, Kelly) |
| Oct 8, 2021 | 88 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Rachel Matthew on October 15, 2021 filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Oct 4, 2021 | 87 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of First Responsive Expert Report of Raj Suryanarayanan, Ph.D. filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Sep 21, 2021 | 85 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Rebuttal Expert Report of Stephen G. Kunin filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Sep 21, 2021 | 86 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of the Responsive Expert Report of Richard M. Goldberg, M.D. Regarding Validity Considerations of the '284 and '399 Patents and the Expert Report of Mohan Rao, Ph.D. filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Sep 20, 2021 | 84 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Eugia, Aurobindo and Natco's Responsive Expert Report of Mark Ratain, M.D. filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..(Dorsney, Kenneth) |
| Sep 17, 2021 | N/A | Oral Order (0) Docket Text: ORAL ORDER: Having read the parties' letter dated September 3, 2021, the Court agrees with Taiho that the parties' experts should opine on the competing definitions of the disputed claim term and the Court can resolve the claim construction issue during or after trial. Ordered by Judge Colm F. Connolly on 9/17/2021. Associated Cases: 1:19-cv-02321-CFC, 1:19-cv-02342-CFC-JLH, 1:19-cv-02368-CFC-JLH(nmf) |
| Sep 17, 2021 | 82 | Stipulation (5) Docket Text: Joint STIPULATION Stipulation and [Proposed] Order to Amend Scheduling Order by MSN Laboratories Private Ltd., MSN Pharmaceuticals Inc., Accord Healthcare Inc.. (Ormerod, Eve) |
| Sep 17, 2021 | 83 | SO ORDERED (5) Docket Text: SO ORDERED, re (80 in 1:19-cv-02342-CFC-JLH, 82 in 1:19-cv-02368-CFC-JLH, 67 in 1:19-cv-02321-CFC) Joint STIPULATION Stipulation and Order to Amend Scheduling Order. Signed by Judge Colm F. Connolly on 9/17/2021. Associated Cases: 1:19-cv-02321-CFC, 1:19-cv-02342-CFC-JLH, 1:19-cv-02368-CFC-JLH(nmf) |
| Sep 7, 2021 | 80 | Main Document (5) Docket Text: REDACTED VERSION of [73] Letter by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Attachments: # (1) Exhibit 1-13)(Balick, Steven) |
| Sep 7, 2021 | 80 | Exhibit 1-13 (617) |
| Sep 7, 2021 | 81 | Redacted Document (2) Docket Text: REDACTED VERSION of [74] Declaration of Liane M. Peterson by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Balick, Steven) |
| Sep 3, 2021 | N/A | Redaction Notice (0) Docket Text: REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI # [73] and [74]. (ceg) |
| Sep 3, 2021 | 79 | Letter (5) Docket Text: Letter to The Honorable Colm F. Connolly from Eve H. Ormerod, Esq. regarding Request for Early Claim Construction Hearing with Expedited Briefing. (Ormerod, Eve) |
| Aug 30, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, [78] Stipulation to Extend Plaintiffs' Redactions Deadlines for Discovery Dispute Answering Letter (D.I. 73) and Supporting Declaration (D.I. 74) to August 26, 2021. ORDERED by Judge Jennifer L. Hall on 8/30/2021. (ceg) |
| Aug 24, 2021 | 77 | Main Document (5) Docket Text: REDACTED VERSION of [72] Declaration by Natco Pharma Ltd., Natco Pharma, Inc.. (Attachments: # (1) Exhibit 1-10)(Farnan, Kelly) |
| Aug 24, 2021 | 77 | Exhibit 1-10 (149) |
| Aug 24, 2021 | 78 | Stipulation (2) Docket Text: STIPULATION Seeking to Extend Plaintiffs' Redactions Deadlines for Their Discovery Dispute Answering Letter (D.I. 73) and Supporting Declaration (D.I. 74), by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Balick, Steven) |
| Aug 20, 2021 | N/A | Discovery Conference (0) Docket Text: Minute Entry for proceedings held before Judge Jennifer L. Hall - Discovery Dispute Telephone Conference held on 8/20/2021. (*Court Reporter Jennifer Guy.) (ceg) |
| Aug 20, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, [75] Stipulation to Extend Time for Defendants to file a public version of the Declaration of Christopher J. Sorenson in Support of Motion to Strike to August 23, 2021. ORDERED by Judge Jennifer L. Hall on 8/20/2021. (ceg) |
| Aug 20, 2021 | N/A | Oral Order (0) Docket Text: ORAL ORDER: IT IS HEREBY ORDERED that the transcript of the August 20, 2021 discovery dispute teleconference shall serve as the Order of the Court. The parties shall meet and confer and submit a stipulation as discussed during the teleconference. ORDERED by Judge Jennifer L. Hall on 8/20/2021. (ceg) |
| Aug 19, 2021 | 75 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME for Defendants to file a public version of the Declaration of Christopher J. Sorenson in Support of Motion to Strike to August 23, 2021 - filed by Natco Pharma Ltd., Natco Pharma, Inc.. (Farnan, Kelly) |
| Aug 12, 2021 | 71 | Main Document (3) Docket Text: Letter to The Honorable Jennifer L. Hall from Kelly E. Farnan regarding discovery dispute. (Attachments: # (1) Text of Proposed Order)(Farnan, Kelly) |
| Aug 12, 2021 | 71 | Text of Proposed Order (1) |
| Aug 10, 2021 | N/A | Order Setting Teleconference (0) Docket Text: ORAL ORDER Setting Teleconference: The Court has reviewed the Motion for Teleconference to Resolve Discovery Dispute (D.I. [69]). A discovery dispute teleconference is scheduled for August 20, 2021 at 10:00 AM Eastern Time before Judge Jennifer L. Hall. By no later than August 12, 2021 the party(ies) seeking relief shall file with the Court a letter, not to exceed three pages, in no less than 12-point font, outlining the issues in dispute and its position on those issues. By no later than August 17, 2021 any party(ies) opposing the application for relief may file a letter, not to exceed three pages, in no less than 12-point font, outlining that party's reasons for its opposition. Counsel is reminded to provide courtesy copies. Counsel shall send dial-in information directly to the Court, no later than 24 hours prior to the hearing, using the following e-mail address: Cailah_Garfinkel@ded.uscourts.gov. The Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Jennifer L. Hall on 8/10/2021. (ceg) |
| Aug 6, 2021 | 69 | Motion for Miscellaneous Relief (2) Docket Text: MOTION for Teleconference to Resolve Discovery Dispute - filed by Natco Pharma Ltd., Natco Pharma, Inc.. Motions referred to Jennifer L. Hall.(Farnan, Kelly) |
| Aug 4, 2021 | N/A | Oral Order (0) Docket Text: ORAL ORDER REFERRING CASE to Magistrate Judge Jennifer L. Hall for all disputes relating to discovery and the protective order. Ordered by Judge Colm F. Connolly on 8/4/2021. (fms) |
| Aug 4, 2021 | N/A | Oral Order (0) Docket Text: ORAL ORDER: A Motion for Teleconference to Resolve Discovery Dispute should be filed if counsel finds they are unable to resolve a discovery matter. The suggested text for this motion can be found in Judge Hall's portion of the Court's website, in the "Forms" tab, under the heading "Motion for Teleconference to Resolve Discovery/Protective Order Disputes." The dispute will thereafter be addressed in accordance with Judge Hall's discovery dispute procedures. ORDERED by Judge Jennifer L. Hall on 8/4/2021. (ceg) |
| Aug 4, 2021 | 68 | Notice Requesting Removal of Co-Counsel (2) Docket Text: NOTICE requesting Clerk to remove Rachel C. Hughey as co-counsel. Reason for request: Left Firm. (Farnan, Kelly) |
| Jul 23, 2021 | 66 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Opening Expert Report of Dr. Allan S. Myerson Regarding Infringement by Natco Pharma Ltd. and Natco Pharma, Inc., Opening Expert Report of Howard S. Hochster, M.D. Regarding Infringement by the Natco Defendants, and Taiho's Disclosure of Second Supplemental Infringement Contentions Concerning Infringement of the Patents-In-Suit by the Natco Defendants filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Balick, Steven) |
| Jul 22, 2021 | 64 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants' (1) Expert Report of Gregory A. Stephenson, Ph.D. Regarding Invalidity of U.S. Patent Nos. 9,527,833 and 10,457,666 and (2) Expert Report of Nicholas P. Godici filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Jul 22, 2021 | 65 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendants' Expert Report of Mark J. Ratain, M.D. Concerning the Invalidity of U.S. Patent No. RE46,284 filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Jun 17, 2021 | 62 | Stipulation (4) Docket Text: STIPULATION and Proposed Order to Extend Time regarding Certain Scheduling Order Deadlines by Natco Pharma Ltd., Natco Pharma, Inc.. (Farnan, Kelly) |
| Jun 17, 2021 | 63 | SO ORDERED (4) Docket Text: SO ORDERED, re (64 in 1:19-cv-02309-CFC, 62 in 1:19-cv-02368-CFC, 61 in 1:19-cv-02321-CFC, 71 in 1:19-cv-02342-CFC) Stipulation filed by Natco Pharma Ltd., Natco Pharma, Inc. Signed by Judge Colm F. Connolly on 6/17/2021. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(fms) |
| Apr 30, 2021 | 61 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Natco's First Set of Requests for Admission (Nos. 1-15) and Plaintiffs' Objections and Responses to Natco's First Set of Interrogatories (Nos. 1-4) filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Apr 29, 2021 | 60 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Natco Pharma Ltd.s and Natco Pharma, Inc.s Response to Plaintiffs First Set of Requests for Admission to Defendants filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Apr 16, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [59] STIPULATION TO EXTEND TIME for the close of fact discovery to April 30, 2021 filed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc. Signed by Judge Colm F. Connolly on 4/16/2021. (fms) |
| Apr 16, 2021 | 59 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME for the close of fact discovery to April 30, 2021 - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Mayo, Andrew) |
| Apr 14, 2021 | 58 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiffs' First Supplemental Objections and Responses to Defendants' First Set of Interrogatories (Nos. 1, 3) filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Apr 12, 2021 | 57 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Defendants' First Set of Interrogatories (Nos. 1-6) filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Mar 17, 2021 | 55 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiffs' First Set of Requests for Admission to Defendants filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Mar 17, 2021 | 56 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Natco Pharma Ltd.s and Natco Pharma, Inc.s First Set of Interrogatories to Plaintiffs (Nos. 1-4) and (2) Natco Pharma Ltd.s and Natco Pharma, Inc.s First Set of Requests for Admissions filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Mar 11, 2021 | 53 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiffs' Supplemental Initial Disclosures filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Mar 11, 2021 | 54 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of First Set of Interrogatories (Nos. 1-6) filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Mar 9, 2021 | 51 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Dr. Pulla Reddy on March 12, 2021 at 9:00 a.m. (IST)/March 11, 2021 at 10:30 p.m. (EST), filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Balick, Steven) |
| Mar 9, 2021 | 52 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Dr. Pavan Bhat on March 15, 2021 at 9:00 a.m. (IST)/March 14, 2021 at 10:30 p.m. (EST), filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Balick, Steven) |
| Feb 25, 2021 | 50 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Dr. Martin Birkhoffer on February 26, 2021 filed by Natco Pharma Ltd., Natco Pharma, Inc..(Delcollo, Renee) |
| Feb 4, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (50 in 1:19-cv-02309-CFC, 54 in 1:19-cv-02342-CFC, 49 in 1:19-cv-02368-CFC, 56 in 1:19-cv-02321-CFC) MOTION for Pro Hac Vice Appearance of Attorney Tiffany K. Sung filed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc. Signed by Judge Colm F. Connolly on 2/4/2021. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(fms) |
| Feb 3, 2021 | 49 | Motion for Leave to Appear Pro Hac Vice (5) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Tiffany K. Sung - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Mayo, Andrew) |
| Jan 14, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [48] Stipulation filed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc. Ordered by Judge Colm F. Connolly on 1/14/2021. (fms) |
| Jan 13, 2021 | 48 | Stipulation (2) Docket Text: STIPULATION and Proposed Order regarding Amended Infringement Contentions by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Mayo, Andrew) |
| Jan 4, 2021 | 47 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Objections to Notice of Rule 30(b)(6) Deposition filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Dec 23, 2020 | 46 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of Taiho Pharmaceutical Co., Ltd.'s and Taiho Oncology, Inc.'s Objections and Responses to Defendants' Notice of Deposition under Fed. R. Civ. P. 30(b)(6) filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Dec 15, 2020 | 45 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendants' Joint Notice of 30(b)(6) Deposition to Plaintiffs filed by Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Inc., Eugia Pharma Specialities Ltd..(Dorsney, Kenneth) |
| Dec 14, 2020 | 44 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of (1) Taiho's Notice of Rule 30(b)(6) Deposition to the Natco Defendants; (2) Taiho's Notice of Rule 30(b)(6) Deposition to the Eugia Defendants; and (3) Taiho's Notice of Rule 30(b)(6) Deposition to the MSN Defendants filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Balick, Steven) |
| Dec 10, 2020 | 43 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Defendants' Joint Second Set of Requests for Production (Nos. 8-53) filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Balick, Steven) |
| Nov 10, 2020 | 42 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants' Joint Second Set of Requests for Production to Plaintiffs (Nos. 8-53) filed by MSN Laboratories Private Ltd., MSN Pharmaceuticals Inc., Accord Healthcare Inc..(Ormerod, Eve) |
| Nov 4, 2020 | 41 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Natco Pharma Inc.s and Natco Pharma, Ltd.s Supplemental Answer to Taihos First Joint Interrogatory to Defendants (No. 1) filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Sep 25, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (48 in 1:19-cv-02342-CFC, 40 in 1:19-cv-02368-CFC, 42 in 1:19-cv-02309-CFC, 50 in 1:19-cv-02321-CFC) STIPULATION TO EXTEND TIME re: the deadline to substantially complete document production to December 4, 2020 filed by Natco Pharma Ltd., Natco Pharma, Inc.. Signed by Judge Colm F. Connolly on 9/25/2020. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(fms) |
| Sep 24, 2020 | 40 | Stipulation to EXTEND Time (3) Docket Text: STIPULATION TO EXTEND TIME re: the deadline to substantially complete document production to December 4, 2020 - filed by Natco Pharma Ltd., Natco Pharma, Inc.. (Farnan, Kelly) |
| Sep 23, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (39 in 1:19-cv-02368-CFC, 41 in 1:19-cv-02309-CFC, 47 in 1:19-cv-02342-CFC, 49 in 1:19-cv-02321-CFC) Stipulation filed by Natco Pharma Ltd., Natco Pharma, Inc.. Signed by Judge Colm F. Connolly on 9/23/2020. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(fms) |
| Sep 23, 2020 | 39 | Stipulation (3) Docket Text: STIPULATION and Proposed Order re Amended Invalidity Contentions by Natco Pharma Ltd., Natco Pharma, Inc.. (Farnan, Kelly) |
| Sep 16, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (48 in 1:19-cv-02321-CFC, 40 in 1:19-cv-02309-CFC, 46 in 1:19-cv-02342-CFC, 38 in 1:19-cv-02368-CFC) STIPULATION and Order Regarding Claim Construction filed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., ORDER, terminating Deadlines and Hearings: The 2/18/2021 Markman Hearing is canceled and all other deadlines relating to claim construction are vacated. Signed by Judge Colm F. Connolly on 9/16/2020. (nmf) |
| Sep 14, 2020 | 38 | Stipulation (7) Docket Text: STIPULATION and Proposed Order Regarding Claim Construction, by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Balick, Steven) |
| Sep 1, 2020 | 37 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Taiho's Preliminary Identification of Claim Terms that Need Construction And Proposed Claim Constructions filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Aug 25, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (38 in 1:19-cv-02309-CFC, 44 in 1:19-cv-02342-CFC, 36 in 1:19-cv-02368-CFC, 43 in 1:19-cv-02321-CFC) STIPULATION TO EXTEND TIME to Exchange Identification of Claim Terms and Proposed Constructions to September 1, 2020 filed by Natco Pharma Ltd., Natco Pharma, Inc. Signed by Judge Colm F. Connolly on 8/25/2020. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(nmf) |
| Aug 25, 2020 | 36 | Stipulation to EXTEND Time (4) Docket Text: STIPULATION TO EXTEND TIME to Exchange Identification of Claim Terms and Proposed Constructions to September 1, 2020 - filed by Natco Pharma Ltd., Natco Pharma, Inc.. (Farnan, Kelly) |
| Aug 12, 2020 | 35 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Defendants Natco Pharma Inc.'s and Natco Pharma, Ltd.'s Supplemental Initial Disclosures Under Fed. R. Civ. 26(A)(1), (2) Defendants Natco Pharma Inc.'s and Natco Pharma, Ltd.'s Supplemental Initial Disclosures Pursuant to the Delaware Default Standard 3, and (3) Defendants Natco Pharma Inc.'s and Natco Pharma, Ltd.'s Answers to Taiho's First Set of Joint Interrogatories to Defendants (Nos. 1-4) filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Aug 11, 2020 | 34 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Joint Initial Invalidity Contentions filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Jul 9, 2020 | 33 | Stipulation to EXTEND Time (5) Docket Text: STIPULATION TO EXTEND TIME to: 1) Submit Invalidity Contentions; 2) Exchange Indentification of Terms and Proposed Constructions; and 3) File Joint Claim Construction Chart to 1) August 11, 2020; 2) August 25, 2020; and 3) September 14, 2020, respectively - filed by Natco Pharma Ltd., Natco Pharma, Inc.. (Farnan, Kelly) |
| Jun 5, 2020 | 32 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Taiho's First Set of Joint Interrogatories to Defendants filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| May 29, 2020 | 31 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Taiho's Disclosure of Infringement Contentions Concerning Infringement of the Patents-In-Suit by the Natco Defendants filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| May 26, 2020 | 28 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Natco Pharma Inc.s and Natco Pharma, Ltd.s Initial Disclosures Pursuant to the Delaware Default Standard Paragraph 3 filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| May 26, 2020 | 29 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Defendants' First Set of Requests for Production (Nos. 1-7) filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| May 26, 2020 | 30 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Natco Pharma Inc.s and Natco Pharma, Ltd.s Responses to Taihos First Set of Requests for Production filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| May 18, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [27] STIPULATION TO EXTEND TIME re: Defendants Natco Pharma Inc. and Natco Pharma, Ltd. to serve their disclosures pursuant to Paragraph 3 of the Default Standard for Discovery to May 28, 2020 filed by Natco Pharma Ltd., Natco Pharma, Inc. Signed by Judge Colm F. Connolly on 5/18/2020. (fms) |
| May 18, 2020 | 27 | Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME re: Defendants Natco Pharma Inc. and Natco Pharma, Ltd. to serve their disclosures pursuant to Paragraph 3 of the Default Standard for Discovery to May 28, 2020 - filed by Natco Pharma Ltd., Natco Pharma, Inc.. (Farnan, Kelly) |
| May 14, 2020 | 26 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiffs' Initial Disclosures related to Electronically Stored Information filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Apr 28, 2020 | 25 | Protective Order (26) Docket Text: PROTECTIVE ORDER. Signed by Judge Colm F. Connolly on 4/28/2020. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(fms) |
| Apr 27, 2020 | 24 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Taiho's First Set of Requests for Production to The Natco Defendants filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Mayo, Andrew) |
| Apr 24, 2020 | 23 | Proposed Order (25) Docket Text: PROPOSED ORDER (Proposed Protective Order) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Mayo, Andrew) |
| Apr 23, 2020 | 22 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Joint First Set of Requests for Production (Nos. 1-7) filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Apr 20, 2020 | 20 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiffs' Initial Disclosures filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd..(Balick, Steven) |
| Apr 20, 2020 | 21 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Natco Pharma, Inc.'s and Natco Pharma, Ltd.'s Initial Disclosures Under Fed. R. Civ. 26(a)(1) filed by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Apr 15, 2020 | N/A | Case Referred to Mediation (0) Docket Text: CASE REFERRED to Chief Magistrate Judge Mary Pat Thynge for Mediation. Please see Standing Order dated January 20, 2016, regarding disclosure of confidential ADR communications. A link to the standing order is provided here for your convenience at https://www.ded.uscourts.gov/sites/ded/files/forms/StandingOrderforADR-Mediation.pdf Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(cak) |
| Apr 14, 2020 | 19 | Scheduling Order (26) Docket Text: SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Joinder of Parties due by 10/23/2020. Amended Pleadings due by 10/23/2020. Fact Discovery completed by 4/6/2021. Expert Discovery due by 12/21/2021. Joint Claim Construction Brief due by 12/14/2020. A Markman Hearing is set for 2/18/2021 at 09:00 AM in Courtroom 4B before Judge Colm F. Connolly. Proposed Pretrial Order due by 6/9/2022. A Final Pretrial Conference is set for 6/30/2022 at 04:00 PM in Courtroom 4B before Judge Colm F. Connolly. A Bench Trial is set for 7/11/2022 at 08:30 AM in Courtroom 4B before Judge Colm F. Connolly. Signed by Judge Colm F. Connolly on 4/14/2020. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(nmf) |
| Apr 13, 2020 | N/A | Remark (0) Docket Text: The April 15, 2020 Scheduling Conference is cancelled per the filing of the Letter and Unopposed Scheduling Order in accordance with the Court's Order of March 12, 2020. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(nmf) |
| Apr 13, 2020 | 17 | Letter (1) Docket Text: Letter to The Honorable Colm F. Connolly from Steven J. Balick regarding the Parties' Jointly Proposed Scheduling Order. (Balick, Steven) |
| Apr 13, 2020 | 18 | Proposed Order (26) Docket Text: PROPOSED ORDER (Proposed Scheduling Order) by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Balick, Steven) |
| Apr 9, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Molly Hayssen for Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(kmd) |
| Apr 3, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorneys B. Jefferson Boggs, Christopher J. Sorenson, Rachel C. Hughey, Karen L. Beckman for Natco Pharma Ltd. and Natco Pharma, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd) |
| Apr 3, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (19 in 1:19-cv-02321-CFC, 18 in 1:19-cv-02309-CFC, 16 in 1:19-cv-02368-CFC, 21 in 1:19-cv-02342-CFC) MOTION for Pro Hac Vice Appearance of Attorney Molly Hayssen filed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc.. Signed by Judge Colm F. Connolly on 4/3/2020. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(fms) |
| Apr 3, 2020 | 16 | Motion for Leave to Appear Pro Hac Vice (5) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Molly Hayssen - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Mayo, Andrew) |
| Mar 31, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [15] MOTION for Pro Hac Vice Appearance of Attorney B. Jefferson Boggs, Jr., Christopher J. Sorenson, Rachel C. Hughey and Karen L. Beckman filed by Natco Pharma Ltd., Natco Pharma, Inc. Signed by Judge Colm F. Connolly on 3/31/2020. (fms) |
| Mar 30, 2020 | 15 | Motion for Leave to Appear Pro Hac Vice (5) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney B. Jefferson Boggs, Jr., Christopher J. Sorenson, Rachel C. Hughey and Karen L. Beckman - filed by Natco Pharma Ltd., Natco Pharma, Inc.. (Farnan, Kelly) |
| Mar 12, 2020 | 14 | Order Setting Scheduling Conference (3) Docket Text: Order Setting Scheduling Conference: A Scheduling Conference is set for 4/15/2020 at 03:30 PM in Courtroom 4B before Judge Colm F. Connolly. If the parties have no disputes about scheduling, the Court will not require the parties to appear at a conference. Signed by Judge Colm F. Connolly on 3/12/2020. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(nmf) |
| Feb 25, 2020 | 13 | Letter (2) Docket Text: Letter to The Honorable Colm F. Connolly from Steven J. Balick regarding Plaintiffs' Response to the Court's January 27, 2020 Order Regarding Coordination of Proceedings. (Balick, Steven) |
| Jan 27, 2020 | 12 | Order (3) Docket Text: ORDER, on or before February 27, 2020, counsel for plaintiffs shall inform the court as to whether the need for coordinated discovery and/or Markman proceedings is anticipated and, if so, when a joint scheduling conference might most efficiently be conducted. ORDER, Setting Deadlines: Notice of Compliance deadline set for 2/27/2020. Signed by Judge Colm F. Connolly on 1/27/2020. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(nmf) |
| Jan 23, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Michael Kaminski for Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(kmd) |
| Jan 23, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Liane M. Peterson for Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(kmd) |
| Jan 23, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Bradley Roush for Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-02368-CFC, 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC(mal) |
| Jan 22, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (10 in 1:19-cv-02342-CFC, 11 in 1:19-cv-02309-CFC, 11 in 1:19-cv-02321-CFC, 11 in 1:19-cv-02368-CFC) MOTION for Pro Hac Vice Appearance of Attorney Michael D. Kaminski, Liane M. Peterson, and Bradley Roush filed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc. Signed by Judge Colm F. Connolly on 1/22/2020. Associated Cases: 1:19-cv-02309-CFC, 1:19-cv-02321-CFC, 1:19-cv-02342-CFC, 1:19-cv-02368-CFC(fms) |
| Jan 22, 2020 | 11 | Motion for Leave to Appear Pro Hac Vice (7) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Michael D. Kaminski, Liane M. Peterson, and Bradley Roush - filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Mayo, Andrew) |
| Jan 21, 2020 | 9 | Answer to Complaint (18) Docket Text: ANSWER to [1] Complaint, by Natco Pharma Ltd., Natco Pharma, Inc..(Farnan, Kelly) |
| Jan 21, 2020 | 10 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate NATCOPHARM for Natco Pharma Ltd. filed by Natco Pharma Ltd., Natco Pharma, Inc.. (Farnan, Kelly) |
| Jan 2, 2020 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. Associated Cases: 1:19-cv-02342-CFC, 1:19-cv-02368-CFC (rjb) |
| Dec 30, 2019 | N/A | Summons Issued (0) Docket Text: Summons Issued with Magistrate Consent Notice attached as to Natco Pharma Ltd. on 12/30/2019; Natco Pharma, Inc. on 12/30/2019. Requesting party or attorney should pick up issued summons at the Help Desk, Room 4209, or call 302-573-6170 and ask the Clerk to mail the summons to them. (mal) |
| Dec 30, 2019 | 1 | Main Document (30) Docket Text: COMPLAINT filed against Natco Pharma Ltd., Natco Pharma, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2812050.) - filed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc.. (Attachments: # (1) Exhibit A-D, # (2) Civil Cover Sheet)(mal) |
| Dec 30, 2019 | 1 | Exhibit A-D (58) |
| Dec 30, 2019 | 1 | Civil Cover Sheet (1) |
| Dec 30, 2019 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mal) |
| Dec 30, 2019 | 3 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 11/21/2019. Date of Expiration of Patent: see attached.Thirty Month Stay Deadline: 3/23/2023. (mal) |
| Dec 30, 2019 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) RE46,284 E ;9,527,833 C1 ;10,457,666 B2. (mal) |
| Dec 30, 2019 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Otsuka Holdings Co., Ltd. for Taiho Pharmaceutical Co., Ltd. filed by Taiho Pharmaceutical Co., Ltd.. (mal) |
| Dec 30, 2019 | 6 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Taiho Pharmaceutical Co., Ltd. for Taiho Oncology, Inc. filed by Taiho Oncology, Inc.. (mal) |
| Dec 30, 2019 | 7 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc.. Natco Pharma Ltd. served on 12/30/2019, answer due 1/21/2020. (Mayo, Andrew) |
| Dec 30, 2019 | 8 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc.. Natco Pharma, Inc. served on 12/30/2019, answer due 1/21/2020. (Mayo, Andrew) |
| Dec 30, 2019 | 1 | Complaint* (1) |
